CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III
CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III
CellProthera和biocardia在ProtheraCytes用於急性心肌梗死的合作II期臨床試驗中取得成功，並計劃繼續關係至III期。
CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in combination with the standard of care, suggested an effective solution for preventing heart failure progression in the patients at high risk following a heart attack.
CellProthera的I/IIb EXCELLENt試驗的臨床結果表明，在與標準板治療聯合給藥的情況下，ProtheraCytes的經內心膜注射對急性心肌梗塞有很好的可行性，該方案對於高風險患者防止心臟衰竭進展具有有效的解決方案。